Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
22.44 USD | +0.18% | -0.00% | +121.20% |
Jun. 02 | Transcript : Cullinan Therapeutics, Inc. - Special Call | |
Jun. 01 | Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+121.20% | 1.29B | |
+47.02% | 57.87B | |
+40.68% | 40.25B | |
-6.52% | 39.94B | |
-5.16% | 28.54B | |
+11.11% | 26.4B | |
-20.58% | 19.33B | |
+30.53% | 12.4B | |
-1.41% | 12.23B | |
+23.14% | 12.2B |
- Stock Market
- Equities
- CGEM Stock
- News Cullinan Therapeutics, Inc.
- Cullinan Oncology : Morgan Stanley Upgrades Cullinan Management to Overweight from Equalweight, Sets $40 Price Target